Analysis: The Post-Pandemic Future of China’s Vaccine Industry

(Blue View) — The nearly three-year-old Covid-19 pandemic drove a surge of global investment into the development of vaccines, creating huge profits for drugmakers. But as the pandemic wanes, will the growth be sustained?

Covid shots have become the major revenue booster for companies that successfully launched products. Chinese vaccine maker, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., whose recombinant protein Covid-19 vaccine won Chinese approval in March 2021, reported 30.65 billion yuan ($4.57 billion) in revenue that year, nearly double from a year earlier.